Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years symbols : RETA save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.33%
H: 0.35%
C: -1.5%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.67%
H: 0.85%
C: 0.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.8%
H: 0.46%
C: -2.44%
companies therapeutics growth market
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 3.35%
H: 25.0%
C: 4.17%
berubicin ongoing pharmaceuticals study
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
SMMT A | $3.51 0.0% 1.7M
|
Health Technology
|
| O: -0.46%
H: 6.68%
C: -11.75%
PLSE | $7.2 -2.17% -2.22% 180K
|
Health Technology
|
| O: 0.39%
H: 6.43%
C: 1.92%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.82%
H: 0.73%
C: -0.4%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
therapeutics financial results
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
Biogen Completes Acquisition of Reata Pharmaceuticals
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.02%
H: 1.37%
C: 1.21%
acquisition pharmaceuticals
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.31%
H: 1.04%
C: 0.76%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
berubicin pharmaceuticals therapy results study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
Biogen to Acquire Reata Pharmaceuticals
Published: 2023-07-28 (Crawled : 11:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 51.72%
H: 1.55%
C: 1.52%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.19%
H: 1.88%
C: 0.73%
pharmaceuticals acquire
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.1%
H: 5.34%
C: 0.82%
skyclarys approval pharmaceuticals commercial
Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast 2023-2032: With Focus on United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Published: 2023-06-28 (Crawled : 02:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: -0.94%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: -2.09%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.1%
H: 5.34%
C: 0.82%
disease japan kidney market
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.5%
H: 0.81%
C: -3.62%
skyclarys fda approval pharmaceuticals
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Published: 2023-06-13 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.83%
H: 7.38%
C: 6.11%
pharmaceuticals research
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published: 2023-06-09 (Crawled : 10:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.15%
H: 0.96%
C: -0.17%
potential
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published: 2023-05-31 (Crawled : 09:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.02%
H: 1.4%
C: 0.37%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.88%
H: 4.78%
C: 2.26%
potential
TCBI ALERT: The Law Offices of Vincent Wong Investigate Texas Capital Bancshares, Inc. for Potential Violations of Securities Laws
Published: 2023-05-31 (Crawled : 09:00) - prnewswire.com
TCBI | $58.635 4.74% 4.53% 830K
|
Finance
|
| O: -0.31%
H: 0.33%
C: -3.51%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.02%
H: 1.4%
C: 0.37%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.88%
H: 4.78%
C: 2.26%
potential
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published: 2023-05-31 (Crawled : 09:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.02%
H: 1.4%
C: 0.37%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.88%
H: 4.78%
C: 2.26%
potential
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published: 2023-05-30 (Crawled : 09:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.34%
H: 0.55%
C: -2.5%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.26%
H: 2.71%
C: -3.31%
potential
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published: 2023-05-30 (Crawled : 09:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.34%
H: 0.55%
C: -2.5%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.26%
H: 2.71%
C: -3.31%
potential
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.